Theracos

Quick facts

Marketed products

• Bexagliflozin tablets · Diabetes
  Bexagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels.
• Placebo for Glimepiride · Diabetes
  A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.

Phase 3 pipeline

• Placebo for Bexagliflozin
  Placebo does not have a known mechanism of action.

Phase 2 pipeline

• EGT0001442
  EGT0001442's mechanism of action is currently unknown.
• THR-4109

Phase 1 pipeline

• EGT0001474
• Sertraline plus Telenzepine

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Theracos portfolio CI brief
• Theracos pipeline updates RSS